Acceleron Pharma Announces the Initiation of the Gynecologic Oncology Group Phase 2 Clinical Trial of Dalantercept (ACE-041) in Patients With Endometrial Cancer

Published: Nov 14, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with recurrent or persistent endometrial cancer. Dalantercept is a novel protein therapeutic that inhibits angiogenesis by targeting the activin receptor-like kinase 1 (ALK1) pathway. The phase 2 study will enroll approximately 52 patients with recurrent or persistent endometrial carcinoma at multiple sites in the United States. The National Cancer Institute will provide financial support for the trial through its Cancer Therapy Evaluation Program (CTEP).

Back to news